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Abstract
Background: Ewing sarcoma family of tumors (ESFT), characterized by t(11;22)(q24;q12), is one of the most
common tumors of bone in children and young adults. In addition to EWS/FLI1 gene fusion, copy number changes
are known to be significant for the underlying neoplastic development of ESFT and for patient outcome. Our
genome-wide high-resolution analysis aspired to pinpoint genomic regions of highest interest and possible target
genes in these areas.
Methods: Array comparative genomic hybridization (CGH) and expression arrays were used to screen for copy
number alterations and expression changes in ESFT patient samples. A total of 31 ESFT samples were analyzed by
aCGH and in 16 patients DNA and RNA level data, created by expression arrays, was integrated. Time of the
follow-up of these patients was 5–192 months. Clinical outcome was statistically evaluated by Kaplan-Meier/
Logrank methods and RT-PCR was applied on 42 patient samples to study the gene of the highest interest.
Results: Copy number changes were detected in 87% of the cases. The most recurrent copy number changes
were gains at 1q, 2, 8, and 12, and losses at 9p and 16q. Cumulative event free survival (ESFT) and overall survival
(OS) were significantly better (P < 0.05) for primary tumors with three or less copy number changes than for
tumors with higher number of copy number aberrations. In three samples copy number imbalances were detected
in chromosomes 11 and 22 affecting the FLI1 and EWSR1 loci, suggesting that an unbalanced t(11;22) and
subsequent duplication of the derivative chromosome harboring fusion gene is a common event in ESFT. Further,
amplifications on chromosomes 20 and 22 seen in one patient sample suggest a novel translocation type between
EWSR1 and an unidentified fusion partner at 20q. In total 20 novel ESFT associated putative oncogenes and tumor
suppressor genes were found in the integration analysis of array CGH and expression data. Quantitative RT-PCR
to study the expression levels of the most interesting gene, HDGF, confirmed that its expression was higher than
in control samples. However, no association between HDGF expression and patient survival was observed.
Conclusion: We conclude that array CGH and integration analysis proved to be effective methods to identify
chromosome regions and novel target genes involved in the tumorigenesis of ESFT.
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Background
The Ewing sarcoma family of tumors (ESFT) is a group of
highly aggressive and often metastatic small round cell
tumors characterized by specific t(11;22)(q24;q12) chro-
mosomal rearrangements, which create the EWS/FLI1
gene fusion and thereby a chimeric, oncogenic transcrip-
tion factor [1]. ESFT is one of the most common bone and
soft tissue tumors in children and young adults arising
generally during the second decade of life [2,3]. The ESFT
tumors are divided into four subtypes according to the
histopathological description: classical Ewing sarcoma in
bones, extraskeletal Ewing sarcoma, peripheral neuroepi-
thelioma (PNET), and Askin's tumor. Most of these ESFT
cases manifest defects in the maintenance of genomic sta-
bility with subsequent DNA copy number alterations.
Conventional CGH and array CGH studies have shown
that 63–84% of ESFT patient samples have copy number
changes [4-9]. These copy number alterations play a sig-
nificant role in the tumorigenesis and malignant progres-
sion of solid tumors. The diagnosis and clinical
management of patients would substantially benefit from
identification of these novel chromosomal targets and
molecular markers involved in the tumorigenesis of ESFT,
since secondary genetic alterations in ESFT have been
shown to correlate with patient's outcome. In addition to
overall number of chromosomal imbalances [10,11],
gains of 1q, 8 and 12 and losses of 9p21.3 and 16q have
been associated with poor clinical outcome [7,12-14].
Rapid development of microarray technology has led to
more sophisticated analyses, which can be utilized to find
novel tumor specific genetic alterations. Further, numer-
ous studies have demonstrated that integrating genomic
data from different sources, e.g. at RNA and DNA level,
can enhance the reliability of genetic analysis in under-
standing tumor progression. Our aim was to identify com-
mon regions of gain and loss and to define the influence
of copy number alterations on gene expression to identify
chromosomal areas and genes involved in malignant pro-
gression of Ewing sarcoma. We used high-resolution
array-based CGH to screen simultaneously multiple loci
for possible copy number imbalances in ESFT patient
samples. This approach enables us to detect both large-
scale and gene-size copy number alterations down to ~35
kb in size. To investigate the impact of copy number
imbalances on the gene expression levels of affected
genes, we performed also an expression array analysis to
combine RNA and DNA level data and validated the most
interesting result by quantitative RT-PCR analysis.
Methods
Patient samples and clinical data
Fresh frozen samples (stored at -70°C) were collected
from the archives of the Laboratory of Oncologic
Research, Istituti Ortopedici Rizzoli (IOR), Bologna. A
total of 31 tumor specimens of from ESFT patients treated
at IOR between years 1992 and 2005 were available for
the aCGH study. In order to study ESFT expression pro-
files, 42 patient samples were collected for RNA extrac-
tion. To validate the ESFT diagnosis, the presence of EWS/
FLI or EWS/ERG translocation was confirmed by RT-PCR
for all samples with available RNA. Clinical data for 31
samples (Table 1) used in aCGH and in data integration
analysis were collected from the patient records at IOR. All
patients were treated within controlled prospective trials
[15,16]. The mean age of the patients was 20.7 years, rang-
ing from 5 to 41 years and the male-to-female ratio was
22:9 (2.4). Of the 31 samples used in aCGH analysis, 23
were primary tumors, two recurrencies, and six metastatic
tumors. The majority of these patients (22/31) were diag-
nosed with classical Ewing sarcoma, four with soft tissue
Ewing sarcoma, three with Askin's tumor and two with
PNET. Seven of the patients with primary tumors had
metastases at the time of diagnosis. Sixteen tumors had
Type 1 (exon 7 of EWS/exon 6 of FLI1) gene fusion, eight
had other types of fusion (Type 2: exon 7 of EWS/exon 5
of FLI1 or Type 3: exon 10 of EWS/exon 6 of FLI1), three
samples were negative for the most common fusion genes
(EWS-FLI1 and EWS-ERG), and in four cases this informa-
tion was not available. The sample set was handled in a
coded fashion and the collected clinical and quality con-
trol data of the samples is publicly available in a microar-
ray database at http://www.cangem.org[17]. This study
has been reviewed and approved by the Ethical Review
Board of Helsinki University Central Hospital.
Nucleic acid isolation
Genomic DNA from 31 samples was extracted using the
standard phenol-chloroform method. Prior to extraction,
the proportion of tumor cells was verified to exceed 75%
in all samples by using hematoxylin and eosin-stained
sections. Tissue necrosis was evaluated on the whole
tumor mass. In cases with high percentages of necrosis,
nucleic acids were isolated from the tissue samples in
which viable cells were still present. Reference DNAs,
male and female, were extracted from pooled blood sam-
ples (4 individuals) obtained from Blood Service, Red
Cross, Finland. RNA from 42 ESFT samples was isolated
using a TRIzol extraction kit (Invitrogen Ltd., Paisley, UK)
according to the manufacturer's instructions. Both high
quality genomic DNA and RNA were available for 16
patients after the nucleic acid extraction instead of 42
patients, due to insufficient amount of starting material.
DNA and RNA concentrations were measured using a
GeneQuant pro spectrophotometer (Amersham Pharma-
cia, Cambridge, UK), and RNA quality was assessed using
Agilent's 2100 Bioanalyzer (Agilent, Palo Alto, CA).B
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Table 1: Clinical data of the ESFT patients included in array CGH and/or data integration analysis.
Code Included in 
data 
integration 
analysis
Diagnosis Origin
of sample
Chemotherapy 
or radiation 
before sample 
collection
Material 
from
Necrosis Patient Status 
at Diagnosis
Age Sex Location Outcome
EFS
EFS 
months
Outcome
OVS
OVS 
months
Type of 
Translocation
D150 X Ewing PRI no Biopsy Localized 23 M Femur REL 6 DEAD 12 EWS/FLI-1
type 2
D152 X Ewing PRI no Biopsy Pri Met Lung 15 M Pelvis REL 8 DEAD 17 EWS/FLI-1
type 2
D153 X Ewing PRI no Biopsy Pri Met Bone 22 M Pelvis REL 0 DEAD 5 EWS/FLI-1
type 3
D154 X Ewing PRI yes Resection 50% Localized 19 M Humerus REL 19 AWD 57 Neg/Neg
D155 Ewing PRI no Biopsy Localized 15 F Pelvis NED 69 NED 69 EWS/FLI-1
type 1
D162 Ewing PRI yes Resection 90% Localized 20 M Tibia NED 61 NED 61 Neg/Neg
D239 Ewing PRI yes Resection 95% Localized 21 F Scapula REL 34 NED 41 EWS/FLI-1
type 2
D240 Ewing PRI yes Resection 30% Pri Met Lung 10 F Humerus REL 13 DEAD 15 EWS/FLI-1
type 1
D241 Ewing PRI yes Resection > 95% Localized 28 M Femur NED 47 NED 47 EWS/FLI-1
type 2
D245 Ewing PRI yes Resection 70% Localized 22 M Radius REL 4 DEAD 8 NA
D248 Ewing PRI yes Resection 95% Localized 11 M Scapula NED 76 NED 76 EWS/FLI-1
type 1
D250 Ewing PRI yes Resection 75% Pri Met Lung 32 F Clavicula REL 20 DEAD 31 Neg/Neg
D311 X Ewing PRI no Biopsy Localized 13 M Pelvis NED 43 NED 43 EWS/FLI-1
type 1
D313 X Ewing PRI no Biopsy Localized 24 M Femur REL 18 NED 117 EWS/FLI-1
type 1
D316 X Ewing PRI yes Resection 60% Pri Met Lung 11 M Femur REL 10 DEAD 10 EWS/FLI-1
type 1
D320 X Ewing PRI no Biopsy Localized 5 M Humerus REL 14 DEAD 21 EWS/FLI-1
type 2
D322 X Ewing PRI yes Resection 25% Localized 27 F Femur REL 29 NED 67 EWS/FLI-1
type 1
D242 Ewing Extr PRI no Biopsy Localized 41 F Thorax NED 56 NED 56 NA
D246 Ewing Extr PRI no Biopsy Localized 26 F Thigh NED 49 NED 49 EWS/FLI-1
type 1
D249 Ewing Extr PRI no Biopsy Localized 35 M Thigh REL 7 AWD 13 NA
D252 Ewing Extr PRI no Biopsy Pri Met Lung 18 M Thigh REL 0 DEAD 13 EWS/FLI-1
type 1
D253 Askin's PRI yes Resection 10% Localized 24 M Rib REL 5 DEAD 12 EWS/FLI-1
type 2
D254 Askin's PRI yes Resection 15% Pri Met Lung 21 M Rib NA NA NA NA NA
D156 Askin's REC no Resection Localized 15 M Rib REL 17 DEAD 21 EWS/FLI-1
type 1
D157 X Ewing REC no Amputation Pri Met Lung 30 F Femur REL 3 DEAD 25 EWS/FLI-1
type 1
D255 X Ewing LUNG MET no Resection Pri Met Lung 17 M Scapula REL 31 DEAD 43 EWS/FLI-1
type 1
D256 X Ewing LUNG MET no Resection Localized 34 M Humerus REL 17 NED 136 EWS/FLI-1
type 1
D312 X Ewing LUNG MET no Resection Localized 9 M Fibula REL 28 DEAD 42 EWS/FLI-1
type 1
D321 X Ewing LUNG MET no Lobectomy Localized 24 M Pelvis REL 34 DEAD 80 EWS/FLI-1
type 1
D315 X PNET BONE MET no Biopsy Localized 16 M Tibia REL 58 DEAD 99 EWS/FLI-1
type 1
D257 X PNET BONE MET no Biopsy Localized 16 F Femur REL 6 DEAD 8 EWS/FLI-1
type 2
Extr = extraskeletal; PRI = primary tumor; REC = local recurrence; MET L = metastasis in lung; MET B = metastasis in bone; EFS = event-free survival; REL = relapsed; NED = no evidence of disease; NA = 
not available; OVS = overall survival; AWD = alive with disease.BMC Cancer 2009, 9:17 http://www.biomedcentral.com/1471-2407/9/17
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Array CGH hybridization, microarray image and data 
analysis
Digestion, labeling, hybridization, and data analysis of
genomic DNA was performed according to Agilent's pro-
tocol version 2.0 for 44K arrays as described previously
[18,19]. In brief, the sample and reference DNAs, 7 μg
each, were fragmented and 1.0–1.5 μg of the fragmented
DNA was labeled by random priming using a BioPrime
array labeling kit (Invitrogen, Carlsbad, CA) with Cy3-
dUTP and Cy5-dUTP dyes (Perkin-Elmer, Wellesley, MA).
Labeled samples were purified, combined, and hybridized
for 48 h at 65°C, 10 rpm to Human Genome CGH 44B
oligomicroarray slides (Agilent Technologies Santa Clara,
CA) against gender matched reference DNAs. Then the
arrays were washed and scanned [18]. The array images
were analyzed and data was extracted using Agilent's Fea-
ture Extraction (FE) Software version 8.1, providing dye
normalization (Linear Lowess) and background substrac-
tion. The chromosomal imbalances were identified using
Agilent's CGH Analytics software version 3.4. The altered
chromosomal regions and breakpoints were detected
using ADM-2 (threshold 8.0) with 1.0 Mb window size.
Patient survival analysis was then performed by Kaplan-
Meier and Logrank (Mantel-Cox) methods considering
either event-free or overall survival.
Expression array hybridizations
The ESFT RNA samples, 42 cases and control samples, a
CD34+ cell line and a pool of normal muscle tissue sam-
ples were hybridized to Affymetrix Human Genome U133
Plus 2.0 oligonucleotide microarrays (Affymetrix, Santa
Clara, CA) according to the manufacturer's GeneChip®
One-Cycle Target Labeling-protocol. In brief, 5 μg of total
RNA was reverse transcribed to cDNA using One-Cycle
cDNA Synthesis Kit (Affymetrix). Biotin-labeling of anti-
sense cRNA was carried out using IVT Labeling Kit
(Affymetrix). The labeled and fragmented cRNA (15 μg of
each) was hybridized for 16 h at 45°C in a hybridization
oven 640 (60 rpm). Washing and staining of the arrays
with streptavidin-phycoerythin (SAPE) was completed in
a Fluidics Station 450 (Affymetrix). The arrays were then
scanned using a confocal laser GeneChip Scanner 3000
and images were analyzed using GeneChip Operating
Software (GCOS; Affymetrix, Sacramento, CA). The
expression measurements were preprocessed using
Robust Multi-array Analysis (RMA) for the whole collec-
tion of 44 chips (42 ESFT patients and two hypothetical
normal samples). While only 16 of these were used in the
integration, running the preprocessing for the whole col-
lection (n = 44) provides more accurate estimates of the
true expression levels.
Integration of gene copy number and expression data
In order to compare the measurements obtained on
Affymetrix and Agilent platforms, the sequences used in
the probes were matched to the NCBI36 human genome
build, using the BLAST algorithm to provide a unique
location for each Affymetrix probe set using the target
sequences provided by Affymetrix and each Agilent probe.
Multiple matches were combined to provide a single loca-
tion covering all matches if the resulting sequence length
was below 2,5 Mb. Note that the locations do not neces-
sarily match the reference sequences of the NCBI36
genome, since they correspond to the locations of the
probe sequences, not RefSeqs. In the joint analysis, each
Affymetrix probe set was paired with the closest Agilent
probe, measured as the distance between the mean points
of the sequences. The Affymetrix probe sets that had no
Agilent probes within 375 kb were ignored. Correlation
between expression and gene copy number of different
patients was measured separately for each gene (identified
based on the Affymetrix probe set). Genes with high pos-
itive or negative correlation were chosen for further exam-
ination. The goal of this process was to detect genes where
a copy number change and a change in expression are
observed on the same patients. A similar analysis was con-
ducted by first dividing patients into groups according to
their copy number status and then testing whether these
groups have a significant difference in their expression
levels [20]. Here the correlation approach was chosen
instead of the testing approach, because it can take into
account also small amplification imbalances not detecta-
ble with the method described in Section "Array CGH
hybridization, microarray image and data analysis". It
also takes into account possible higher copy number
changes. As a correlation measure we used Spearman's
rank correlation, since the copy number data does not fol-
low normal distribution. We used the algorithm of Best
[21] to compute the p-value against the correlation being
zero, and corrected for multiple testing by computing
false discovery rates using the q-value procedure [22]. The
correlation was computed only for genes located on chro-
mosome arms where at least 20% of the full patient col-
lection, including also samples not used in the integration
analysis, showed copy number aberration, in order to
focus on regions where associations would be likely.
Quantitative RT-PCT analysis by TaqMan Low Density 
Arrays
Pre-designed TaqMan PCR probe and primer sets for
HDGF  were used: Assay ID Hs00610314-m1 (Applied
Biosystems, Foster City, CA, USA). All PCRs were done by
using ABI PRISM 7900 Sequence Detection System
(Applied Biosystems) as recommended by the supplier.
Thermal cycling conditions were: 50°C for 2 min, 95°C
for 10 min, 95°C for 15 sec and 60°C for 1 min. Gene
expression values were calculated based on the ΔΔCt
method [23], in which RNA from CD34+ cells derived
from human bone marrow and pooled muscle normal tis-
sues derived from three patients were the designated cali-BMC Cancer 2009, 9:17 http://www.biomedcentral.com/1471-2407/9/17
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brators for the analysis of all other samples. CD34+
positive cells and pooled muscle normal tissues were
processed in the same way as tumor samples and used as
separate calibrators for the RT-PCR experiments. For eval-
uating the prognostic value of HDGF, we calculated its
median expression value, and patients were stratified as
"high-expressors" or "low-expressors" relative to the
median value. Patient survival analysis was then per-
formed by Kaplan-Meier and Logrank methods consider-
ing either event-free survival or overall survival.
Results
Copy number changes
Results from a high-resolution analysis of copy number
aberrations in ESFT (n = 31), using Agilent's 44K oligoar-
ray platform and CGH analytics software are shown in
Table 2. In all ESFT patient samples, 0–26 aberrations
were detected per sample (mean: 7.2) and 27 of the 31
samples showed (87%) copy number changes. All sam-
ples without copy number changes (n = 4) were primary
tumors. Metastases (mean: 11.8) showed more copy
number changes than local recurrencies (mean: 9.5) and
primary tumors (mean: 5.8). The sizes of these aberra-
tions ranged from < 60 kb deletions to gains or losses of
whole chromosomes. Among primary tumors, the sam-
ples with low copy number changes (≤ 3 copy number
aberrations) showed a significantly better prognosis with
respect to those with a high number of chromosomal
alterations (> 3 copy number aberrations), both in terms
of event-free and overall survival (Figure 1). Indeed, only
3/11 patients (27%) with less than three copy number
changes developed metastases within 6 years from diag-
nosis in contrast with 8/10 (80%) of those with a high
number of chromosomal alterations (P = 0,03 Fisher's
test), indicating how the number of chromosomal altera-
tions may have a highly prognostic significance despite
the low number of patients here considered. Recurrent
aberrations were gains of 1q (32%), 2 (29%), 8 (67%),
and 12 (29%) and losses at 9p (23%) and 16q (32%) as
visualized in Figure 2. The prominent deletion in 9p21.3
harboring CDKN2A tumor suppressor gene and microde-
letions of these region have been previously described and
discussed in a separate report by Savola et al. [18]. The
gain of chromosome 8 was the most prominent copy
number change in our sample set (21 of 31 cases). Gain of
8q arm (minimal common overlapping area) was present
in all samples with chromosome 8 aberration. The mini-
mal common overlapping area of copy number gain in
chromosome 1 was 1q22-qter. In chromosome 12 the
smallest common region of gain was 12q13.2-q14.1,
which harbors two known oncogenes, ERBB3 and CDK4.
Losses of 16q were observed in three cases together with
1q gain, suggesting the occurrence of an unbalanced
t(1;16). Interesting copy number gains of 11q24.3-qter
and 22q11.12-q12.1 starting or ending, respectively, at
FLI1 and EWSR1 loci, were detected in patient samples
D153 (Fig. 3A–D), D248, and D254 (Table 2). Copy
number imbalances affecting the same loci were detected
also in samples D154 (uncontinuous amplification
22q12.1-q12.1) (Fig. 3F–G), D312 (+11q24.3-qter), and
D315 (-22q12.1) (see Table 2). Original microarray data,
scanned images and FE output text files, are available at
the public repository CanGEM http://www.cangem.org
[17].
Integration of gene copy number and expression data
Array CGH data and expression data were combined for a
total of 16 patient samples (Table 1). Matching of expres-
sion microarray probes to the corresponding copy
number microarray probes using a 375 kb genomic win-
dow yielded 53,145 probe pairs. 10,115 of those located
in chromosomal areas where at least 20% of patients
showed a copy number aberration (1q, 2q, 8q, 12, and
16q). Several putative ESFT-related genes were pin-
pointed, differentially expressed due to copy number
alteration in these chromosomal locations of highest
interest. These novel putative oncogenes and tumor sup-
pressor genes based on our data analysis include 20 genes
(by q-value < 0.20), which previously have not been asso-
ciated with ESFT (Table 3). For a supplementary table with
all integration analysis results see Additional file 1.
Microarray analysis and quantitative RT-PCR on HDGF
Array CGH and expression microarray results on showed
clear evidence that patients with HDGF gain had higher
HDGF expression (Figure 4A–C, correlation 0.81) than
patients without HDGF  gain. However, ESFT patients
could not be divided unambiguously into two groups (see
Figure 4A and 4B) based on this data. To validate HDGF
microarray results, the relative expression levels of HDGF
were analysed by TaqMan Low Density arrays in all 42
available ESFT patient samples (Figure 4F). This analysis
confirmed that ESFT patient samples express higher levels
of HDGF than normal controls. No statistically significant
correlation of HDGF expression with poor clinical out-
come could be shown (Figure 4D and 4E), nor correlation
with patient gender, age or location could be shown. Clin-
ical data summary of these 42 ESFT patients included in
the analysis can be viewed on Additional file 2.
Discussion
In this study, we have performed a comprehensive
genome wide array CGH analysis of 31 EFST patient sam-
ples. Our oligoarray CGH results, the recurrent gains of
1q, 2, 8, and 12, and losses at 9p and 16q that were
present in more than 20% of the patient samples, are in
agreement with previous ESFT studies by G-banding, con-
ventional CGH [4-8] and array CGH [9]. Our array CGH
results revealed complex large-scale changes in several
samples. Gains of DNA sequences were more prevalentBMC Cancer 2009, 9:17 http://www.biomedcentral.com/1471-2407/9/17
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Outcome of patients with low copy number changes (≤ 3 copy number aberrations) and high copy number changes (> 3 copy  number aberrations) Figure 1
Outcome of patients with low copy number changes (≤ 3 copy number aberrations) and high copy number 
changes (> 3 copy number aberrations). Kaplan-Meier plots show A) event-free survival and B) overall survival of patients 
with low copy number changes (≤ 3 copy number aberrations detected in the sample by array CGH) in bold line and with high 
number copy number changes (> 3 copy number aberrations) in hatched line.BMC Cancer 2009, 9:17 http://www.biomedcentral.com/1471-2407/9/17
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than losses and most of the gains affected whole chromo-
somes or chromosome arms. Further, our analysis showed
that patients with low copy number changes (≤ 3 copy
number aberrations) showed a significantly better prog-
nosis than patients with a high number of chromosomal
alterations, both in terms of event-free and overall sur-
vival.
Concomitant gains of 11q24.3-qter and 22q11.21-q12.1
detected in three samples (D153, D248, and D254) sug-
gest that a reciprocal translocation took place between the
EWSR1 and FLI1 loci and thereafter a duplication event of
the derivative chromosome 22. Sample D153 had Type 3
EWS-FLI1 translocation and sample D248 Type 1 translo-
cation, which suggests that the possible duplication event
of the derivative chromosome is not translocation type-
specific. In addition, copy number imbalances affecting
the EWSR1 and/or FLI1 loci were detectedin three other
samples (D154, D312, and D315). In sample D315, with
Type 1 EWS-FLI1  translocation, loss of 22q12.1 was
observed to end at the EWSR1 loci. Similar evidence has
been reported previously [12,13,24]. Our results suggest
that duplication of the der(22)t(11;22) is a common
event in ESFT. Copy number gain of the fusion gene EWS-
FLI1 may further increase the expression of this fusion
product and possibly impair the prognosis. Amplification
or gain of a chimeric fusion gene is relatively infrequent
mechanism in both leukemia and solid tumors. However,
rare cases of gain or amplification of the derivative chro-
mosomes or episomes carrying the fusion gene have been
reported [25-27] and gene dosage effect of the fusion gene
can improve the tumor growth resulting in more aggres-
Chromosomal locations of copy number changes in ESFT patient sample (n = 31) Figure 2
Chromosomal locations of copy number changes in ESFT patient sample (n = 31). The ideogram shows the sum-
mary of gains and losses of DNA sequence copy numbers and their frequencies in ESFT tissue samples (n = 31) analyzed by 
array CGH. Gains (light green) and amplifications (dark green) are shown on the right of each chromosome and losses (red) on 
the left (number refer to the percentage per band). Chromosomal ideogram was generated using the PROGENETIX software 
[46].BMC Cancer 2009, 9:17 http://www.biomedcentral.com/1471-2407/9/17
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Gain of chromosomal material on chromosomes 11 and 22 in patient sample D153 (A-D) and cryptic amplifications on chro- mosomes 20 and 22 in patient sample D154 (E-G) Figure 3
Gain of chromosomal material on chromosomes 11 and 22 in patient sample D153 (A-D) and cryptic amplifi-
cations on chromosomes 20 and 22 in patient sample D154 (E-G). A) Chromosome 11 shows a gain of 11q24.3-qter. 
B) Breakpoint of copy number gain is inside the FLI1 locus. Based on aCGH results, the genomic breakpoint location is 
between 128148010 – 128186180. C) Chromosome 22 shows a gain of 22q11.21-q12.1. D) Breakpoint of copy number gain is 
inside the EWSR1 locus. Genomic breakpoint location is between 28007405 – 28007664. E) Chromosome 20 shows cryptic 
amplifications in 20q11.23, 20q13.12, and 20q13.12-q13.13, gain of 20q13.2-qter, and loss of 20q11.23-q13.12. F) Chromosome 
22 shows loss of 20q11.23, uncontinuous amplifications in 22q11.23-q12.1 separated by segments of loss, gain of 20q12.2-
q12.3, and loss of 20q12.3-qter. G) Copy number transition between amplification and gain in 20q12.1 is in the EWSR1 locus.BMC Cancer 2009, 9:17 http://www.biomedcentral.com/1471-2407/9/17
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Table 2: Array CGH results (n = 31) in ESFT patient samples arranged by diagnosis.
Code Diagnosis Origin of sample Array CGH results Number of changes CDKN2A
deletion status1
D150 Ewing PRI +1q, +2, +4, +6, +7, +8, -10, +12, -16q, +17, -19, 
+20
12 No deletion 2
D152 Ewing PRI +5, +7, +8, +21 4 No deletion 2
D153 Ewing PRI +1, -2q35-qter, +6, +8, +9p, -9q34.11, -10, 
+11q24.3-qter, +12, +16p, +19, +20q12-qter, 
+22q11.21-q12.1
13 No deletion 2
D154 Ewing PRI -3p13, -3p25.1-p25.3, -6q21, -6q24.1-q24.2, 
+8p11.21-p21.2, -8p21.3-pter, +8q, -9q, 
amp20q11.23, -20q11.23-q13.12, amp20q13.12-
q13.2, +20q13.2-qter, -22q11.23, amp22q12.1-
q12.1 (uncontinuous), +22q12.2-q12.3, -22q12.3-
qter
16 No deletion 2
D155 Ewing PRI No changes detected 0 No deletion 2
D162 Ewing PRI -9p21.2-p21.3 1 Heterozygous deletion 2
D239 Ewing PRI No changes detected 0 No deletion 2
D240 Ewing PRI +1q22-qter, +12, +Xq26.3-qter 3 No deletion 2
D241 Ewing PRI No changes detected 0 No deletion 2
D245 Ewing PRI +4q25-qter, +5, +8, +13q11-q12.2 4 No deletion 2
D248 Ewing PRI +1, +2q21.2-q33.1, amp 2q31.2-q33.1, -2q33.2-qter, 
-4, +8, del 9p21.3, -10, +11q24.3-qter, +12, +14, -
16p12.3, -16q, +17p, -17q, +22q11.21-q12.1
16 Homozygous deletion 2
D250 Ewing PRI -3q13.31-q22.3, del 9p21.3, -Xp11.3 3 Homozygous deletion 2
D311 Ewing PRI +1q22-qter, +8, -10p15.3, -16q, +17q21.31-qter, -
19q13.43
6 No deletion 3
D313 Ewing PRI +2, +8 2 No deletion 3
D316 Ewing PRI +2, +8, +14q11.2-q13.2, -14q13.3-q21.1, +14q21.1-
qter, -X
6 No deletion 3
D320 Ewing PRI +8 1 No deletion 3
D322 Ewing PRI +8, -16q, +19p 3 No deletion 3
D242 Ewing Extr PRI +1q 1 No deletion 2
D246 Ewing Extr PRI No changes detected 0 No deletion 2
D249 Ewing Extr PRI -1p34.3-pter, +3p22.1-pter, -6p11.2-p21.31, +8, -
10q23.1, +10q25.1-qter, -13q13.3-q14.3, +13q21.1-
q22.1, +15q21.3-q22.2, +19q13.31-qter, +20q13.33
11 No deletion 2
D252 Ewing Extr PRI +2, +5, +6, -7, +8, -9p21.3, +12, +14, +21, -X 10 Homozygous deletion 2
D253 Askin's PRI +8, -Y 2 No deletion 2
D254 Askin's PRI +2, +3, -4q34.3-qter, -5, +6, -7, -9, del 9p21.3, -10, 
+11q24.3-qter, +12, -13, +14, +16, +18, +19, +20, 
+21, +22q11.21-q12.1
19 Homozygous deletion 2
D157 Ewing REC +2p, +2q11.2-q22.3, -3q13.13-q13.33, +4q31.3-
qter, +8, +12p, +12q12-q21.31, -16q, -17p, -19, +X
11 No deletion 2
D156 Askin's REC +1q, +8p11.21-p11.22, +8p23.1-pter, +8q, 
+11q12.3-q13.2, +12q13.2-q14.1, -16q, +19p
8 No deletion 2
D255 Ewing MET +1q, +2, +5, +6, +8, +12, +13, +15, -16, -17, +18, -
19, +20, +21
14 No deletion 2
D256 Ewing MET -1q24.2-q25.3, +8 2 No deletion 3
D312 Ewing MET +1, +2p, +2q11.2-q21.3, -3, -4, -5q, +6p, +6q12, -
6q13-qter, +7q, +8, +9, -10, -11p, -11q12.1-q24.2, 
+11q24.3-qter, +12, -13, +14, +15q15.2-qter, -16q, 
-17, -18, -19, +20, +X
26 No deletion 3
D321 Ewing MET +2, +5, +6, +8, +14, +15, -16q, -20p, +21, -
Xp11.21-p11.22, -Xq
11 No deletion 3
D257 PNET MET +1p11.2-p13.2, +1p22.1-p32.3, +1p35.1-pter, +1q, -
3p24.3-p25.1, +6q23.1-qter, +7, +8q, -9p, +9q22.1-
q33.3, +12p, +12q12-q15
12 Heterozygous deletion 2
D315 PNET MET -7p, -9p21.1-p21.3, del 9p21.3, -16q, -22q12.1, -
22q13.2-q13.32
6 Homozygous deletion 3
1CDKN2A deletion was regarded as homozygous if the copy number log2 ratio was < -2.0 and as heterozygous if the ratio was -1.5 to -2.0. 2CDKN2A 
deletion result published previously by Savola et al. [18] in an article, which included total of 26 ESFT patient samples. 3CDKN2A deletion status not 
published before.
Extr = extraskeletal; PRI = primary tumor; REC = local recurrence; MET = metastasis.BMC Cancer 2009, 9:17 http://www.biomedcentral.com/1471-2407/9/17
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sive course of disease [27]. Unfortunately our sample set
was not large enough in statistical power to study this
aspect.
Interestingly, sample D154, which was negative for EWS-
FLI1 translocation types that we tested, showed cryptic
amplifications on chromosomes 20 and 22 (Figs. 3E and
3F). Szuhai et al. have reported a similar case with 20q
and 22q amplifications, suggesting that the translocation
Table 3: Putative target genes for tumorigenesis and tumor progression in recurrent copy number changes of the 16 ESFT patients 
included in the integration analysis.
Symbol Name Cytoband Location1 Correlation p-value Copy number 
status2
q-value Functional 
information
HEATR3 HEAT repeat 
containing 3
16q12.1 48697286–
48697733
0,876 2,2E-16 Deleted 6,05E-13 NA
TRAFD1 TRAF-type zinc 
finger domain 
containing 1
12q24.12 111075038–
111075556
0,853 2,2E-16 Gained 6,05E-13 [47]
C1orf131 Chromosome 1 
open reading frame 
131
1q42.2 229426179–
229426672
0,850 2,2E-16 Unspecified 6,05E-13 NA
HDGF Hepatoma-derived 
growth factor
1q21-q23 154978607–
154979115
0,844 1,5E-05 Gained 0,024182394 [34,36-38]
DDX47 DEAD (Asp-Glu-Ala-
Asp) box 
polypeptide 47
12p13.1 12873623– 
12874134
0,844 1,5E-05 Gained 0,024182394 [48]
GIGYF2 GRB10 interacting 
GYF protein 2
2q37.1 233431003–
233431539
0,838 3,5E-05 Unspecified 0,047741159 [49-51]
C2orf49 Chromosome 2 
open reading frame 
49
2q12.2 105331075–
105331416
0,832 5,9E-05 Unspecified 0,069391132 NA
TMEM63A Transmembrane 
protein 63A
1q42.12 224110806–
224111244
0,829 7,3E-05 Gained 0,07491325 NA
WDR67 WD repeat domain 
67
8q24.13 124233227–
124233523
0,826 8,8E-05 Gained 0,080319015 NA
GSDMD1 Gasdermin D 8q24.3 144710202–
144710602
-0,821 1,3E-04 Gained 0,107927089 NA
GPATCH2 G patch domain 
containing 2
1q41 215848737–
215849264
0,812 1,8E-04 Unspecified 0,137376561 NA
WSB2 WD repeat and 
SOCS box-
containing 2
12q24.23 116955326–
116955682
0,809 2,1E-04 Unspecified 0,142275217 [42]
CACNA1C Calcium channel, 
voltage-dependent, L 
type, alpha 1C 
subunit
12p13.3 2670999–
2671234
-0,803 2,7E-04 Deleted 0,160672631 [40,41]
KRT79 Keratin 79 12q13.13 51501640–
51502010
-0,800 3,0E-04 Unspecified 0,160672631 NA
PPHLN1 Periphilin 1 12q12 41121456–
41121979
0,797 3,2E-04 Gained 0,160672631 [43,44]
C1orf107 Chromosome 1 
open reading frame 
107
1q32.2 208096981–
208097464
0,794 3,5E-04 Gained 0,160672631 NA
FBXL14 F-box and leucine-
rich repeat protein 
14
12p13.33 1570852–
1571348
0,794 3,5E-04 Unspecified 0,160672631 NA
ANKRD11 Ankyrin repeat 
domain 11
16q24.3 87999533–
87999771
0,794 3,5E-04 Deleted 0,160672631 [45,52]
HEATR1 HEAT repeat 
containing 1
1q43 234815741–
234816376
0,791 3,9E-04 Gained 0,160672631 NA
COG2 Component of 
oligomeric golgi 
complex 2
1q42.2 228895774–
228896323
0,791 3,9E-04 Gained 0,160672631 [39]
1Location of the Affymetrix target sequence using BLAST algorithm. 2Copy number status = characterization of the copy number status in the 
whole patient set; unspecified indicates that both amplifications and deletions were found. NA = not available.BMC Cancer 2009, 9:17 http://www.biomedcentral.com/1471-2407/9/17
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Correlation of HDGF copy number and expression by microarray analysis and validation of HDGF expression using RT-PCR Figure 4
Correlation of HDGF copy number and expression by microarray analysis and validation of HDGF expression 
using RT-PCR. A) HDGF copy number ratio and B) HDGF expression ratio by microarray analysis in ESFT patient samples (n 
= 16). The patients in figure A) and B) are in the same order, and labelled according to the codes of the DNA samples. C) Cor-
relation of HDGF copy number and expression ratio (correlation 0.844, P < 0.001, q-value 0.024). D) HDGF expression in ESFT 
patient samples (n = 42) by RT-PCR analysis, on y-axis refers to log of fold-change in HDGF gene expression and x-axis to 
patients RNA code number. Kaplan-Meier plots of ESFT patient (n = 42) survival according to D) event-free survival and E) 
overall survival, patients with high expression of HDGF in bold line and patients with low expression in hatched line.BMC Cancer 2009, 9:17 http://www.biomedcentral.com/1471-2407/9/17
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partner of EWSR1 is at 20q [28]. However, the specific
chromosomal region in 20q remained unknown. Based
on our results, the translocation partner of EWSR1  on
chromosome 20 might reside in the amplification break-
point, either at 20q11.23 or 20q13.12-q13.2 (Fig. 2E).
Putative translocation partners of EWSR1  are therefore
genes assigned to the breakpoints of these amplifica-
tions:RPN2, BLCAP, CDH22, SLC13A3, EYA2, NCOA3,
Kua-UEV, and NFATC2. Based on literature, the most
interesting candidates are EYA2  (located at 20q13.12),
which has been found to function as a transcriptional acti-
vator in ovarian cancer cells [29], and NFATC2 (located at
20q13.2), which functions in positive regulation of tran-
scription [30]. Both EYA2 and NFATC2 are oriented on
the amplification breakpoints so that they are in the cor-
rect direction for transcription after the possible fusion
event. In addition to the chromosome 20, genes on region
8p are interesting as putative fusion partners, since many
of these genes are involved in carcinomas and sarcomas.
Indeed the region of 8p11.21-p21.2 was gained in patent
sample D154. However, the possible involvement of
8p11.21-p21.2 as a location of the translocation partner
for EWSR1 was ruled out since this region was not ampli-
fied like EWSR1 was. We would assume that the fusion
partners would be amplified on the same scale, since
translocation is likely to take place before the amplifica-
tion of the fusion gene.
According to our integrated analysis of array CGH and
expression data including 16 ESFT patient samples, we
selected as one of the most interesting putative target
genes within the common 1q22-qter gain gene HDGF,
which has been reported as a putative prognostic marker
for several tumor types, e.g., gastrointestinal stromal
tumors (GIST) [31,32], hepatocellular carcinoma [33],
non-small-cell lung carcinoma [34,35] and pancreatic
ductal carcinoma [36]. HDGF has been shown to stimu-
late cell proliferation and growth after nuclear transloca-
tion [37,38], which makes it a likely target also in ESFT.
Furthermore, our preliminary results from an aCGH anal-
ysis of ESFT cell lines showed that HDGF was inside the
minimal common overlapping area of 1q21.1-q23.1
(Savola et al, unpublished results). Our RT-PCR analysis
confirmed that Ewing's sarcoma cells expressed higher lev-
els of HDGF  with respect to putative normal controls
(CD34 positive cells and normal muscle tissues). How-
ever, when we analyzed HDGF expression level correla-
tion with patient survival, no significant association was
seen. So HDGF can play a role in the tumorigenesis and
tumor progression of EFST, but it shows no prognostic
value. However, due to limitations in numbers of patients
(n = 42) included in the HDGF expression study, no defin-
itive conclusions of the outcome evaluation of HDGF
expression in ESFT can be drawn.
Other interesting target genes pinpointed by integration
analysis in 1q include TMEM63A  (1q42.12),  C1orf107
(1q32.2), HEATR1 (1q43), all relatively unknown genes
in their functions and COG2 (1q42.2), gene involved in
various Golgi functions [39]. In chromosome 8 genes
WDR67  (8q24.13) and GSDMDC1  (8q24.3) locating
nearby each other and in chromosome 12 DDX47
(12p13.1) and CACNA1C (12p13.3) [40,41] are interest-
ing targets for further studies. Also potential oncogenes in
ESFT at 12q are WSB2 (12q24.23), which takes part in the
intracellular signalling cascades and has shown to be a
potential biomarker in colorectal cancer [42], PPHLN1
(12q12), which controls cell cycle regulation by modify-
ing expression of cdc7 involved in progression of DNA
replication [43,44] and KRT79 (12q13.13), a member of
human type II keratin gene family. Previously loss of 16q
has been shown to be a sign of poor prognosis in ESFT
[7,13]. Our results suggest that the putative target gene
within this chromosomal area is HEATR3 (16q12.1) or
ANKRD11 (16q24.3), which has been recently identified
to interact with p53 and act as a co-activator in the regula-
tory feedback loop with p53 [45]. Functional studies to
confirm these results are warranted.
Conclusion
This study adds new information regarding gene copy
number changes and their relation to expression in ESFT
providing valuable data for further analysis. In addition,
array CGH showed to be efficient in the detection of a
putative novel translocation in one patient sample and
provided new information about copy number changes of
the EWS/FLI1 fusion gene. Therefore we can conclude that
array CGH analysis and integrated DNA microarray anal-
ysis of global gene expression patterns and gene copy
number imbalances is a powerful method to identify
novel molecular targets and chromosomal regions of
highest interest in ESFT.
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